Navigation Links
PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
Date:5/6/2008

ANNAPOLIS, Md., May 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the first quarter of 2008 will be released on Tuesday, May 13, 2008.

PharmAthene management will be hosting a conference call to discuss its first quarter 2008 financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Tuesday, May 13, 2008 and will last approximately 45 minutes.

The dial-in number within the United States is 866-770-7129. The dial-in number for international callers is 617-213-8067. The participant passcode is 26177716.

A replay of the conference call will be available for 30 days, beginning at approximately 6:30 p.m. Eastern Time on May 13, 2008 until approximately 11:50 p.m. Eastern Time June 13, 2008. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 15975144.

The conference call will also be webcast and can be accessed from the company's website at http://www.pharmathene.com. A link to the webcast may be found on both the Home Page and also under the Investor Relations section of the website. The webcast will be available for 30 days, or until approximately June 13, 2008.

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed in March 2001 with a mission to become the premier company worldwide specializing in the development and commercialization of therapeutic and prophylactic products for defense against biological and chemical threats. Since its inception, PharmAthene has pursued an acquisitive growth strategy focused on high priority, next generation biodefense products that the government has expressed a clear need and intent to procure. PharmAthene's portfolio currently includes five potential best- in-class biodefense medical countermeasures: Recombinant Protective Antigen (rPA) anthrax vaccine; Valortim(TM), an anthrax anti-toxin therapeutic which is being co-developed with Medarex; Protexia(R) a novel recombinant bioscavenger to prevent and treat organophosphorous nerve agent poisoning; RypVax(TM), a recombinant dual antigen plague vaccine; and finally, third generation rPA anthrax vaccine technology. For more information on PharmAthene, please visit http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:7/20/2017)... DAL ) customers now can use fingerprints instead of their boarding ... ... biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May at the ... to allow eligible Delta SkyMiles Members who are enrolled in CLEAR to ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
Breaking Biology News(10 mins):